IBS随机研究:FODMAPs改变胆酸,和酸代谢物,而质改变脂质
Elise Nordin1, Per M Hellström2, Eddie Vuong1
1Department of Biology and Biological Engineering, Food and Nutrition Science, Chalmers University of Technology, Gothenburg, Sweden.
概括
可发酵的寡糖化物,分糖化物,单糖化物和多 (FODMAPs) 显著改变了刺激性肠综合征 (IBS) 患者的新陈代谢,影响了肠道微生物代谢物. 虽然FODMAPs引起了轻微的症状变化,但它们也显示出积极的健康益处,与质不同.
科学领域:
- 胃肠病学 胃肠病学
- 代谢学 代谢学 代谢学
- 营养科学 营养科学
背景情况:
- 饮食成分与刺激性肠综合征 (IBS) 症状有关,但潜在的机制尚不清楚.
- 代谢学为确定IBS的饮食反应生物标志物提供了一个潜在的途径.
- 了解血代谢组对特定饮食干预措施的反应对于IBS管理至关重要.
研究的目的:
- 为了研究与发酵性寡糖化物,分糖化物,单糖化物和多 (FODMAPs) 或质的干预后IBS患者的血代谢变化.
- 为了将观察到的代谢变化与IBS症状严重程度相关联.
- 探索FODMAP和质对肠道微生物衍生代谢物的影响.
主要方法:
- 这是一项双盲,随机,交叉研究,涉及110名IBS患者.
- 用FODMAPs,质或安慰剂进行的一周干预.
- 使用IBS严重性评分系统 (IBS-SSS) 评估症状.
- 使用LC-qTOF-MS分析的非向血代谢量,用随机森林和线性混合建模分析.
主要成果:
- 代谢组受到FODMAPs的显著改变 (CR 0.88,P < 0.0001),但不太受到质的改变 (CR 0.72,P = 0.01).
- 摄入FODMAP减少了胆酸和增加了基衍生代谢产物和3-烯酸 (IPA).
- 质对脂质代谢的影响很弱,与IBS严重程度没有明显的关联;FODMAPs影响了与积极健康结果相关的微生物代谢物.
结论:
- FODMAPs诱导IBS患者的血代谢中的显著变化,包括肠道微生物衍生代谢物的变化.
- 虽然FODMAPs可能会导致轻微的症状恶化,但它们与健康相关的积极代谢效应值得考虑.
- 在这项研究中,质干预对代谢和IBS严重程度的影响很小.
相关概念视频
Irritable Bowel Syndrome I: Introduction
322
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
322
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
357
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
357
Drugs for Treatment of Constipation-Predominant IBS
225
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
225
Irritable Bowel Syndrome III: Medical and Nursing Management
245
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
245
Drugs for Treatment of Diarrhea-Predominant IBS
217
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
217
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
195
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
195


